![]() |
市場調査レポート
商品コード
1497782
がん診断におけるAI市場:コンポーネント、展開、がんタイプ、エンドユーザー別- 世界予測2024-2030年AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Deployment (Cloud, On-Premise), Cancer Type, End-user - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
がん診断におけるAI市場:コンポーネント、展開、がんタイプ、エンドユーザー別- 世界予測2024-2030年 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
|
がん診断におけるAI市場規模は2023年に2億2,038万米ドルと推定され、2024年には2億6,628万米ドルに達し、CAGR 21.52%で2030年には8億6,250万米ドルに達すると予測されます。
がん診断における人工知能(AI)には、がんの検出、診断、予測のために医療画像やデータを処理、分析、解釈するための高度なアルゴリズムとソフトウェアの使用が含まれます。これらのAI主導型システムは、機械学習や深層学習の機能を備えており、膨大な量の腫瘍学的データから学習し、時間の経過とともに精度と効率を向上させることができます。世界人口におけるがんの有病率の増加と個別化医療のニーズの高まりが、ヘルスケア分野におけるAIの採用を後押ししています。さらに、非侵襲的ながん診断への急激なシフトとともに、世界中のいくつかのがん検診プログラムでの採用が急増していることが、がん治療におけるAIの統合を後押ししています。しかし、AI統合がん治療の高コストと訓練を受けたがん専門医の不足が、がん診断市場におけるAIの拡大に影響を与えています。さらに、政府投資に支えられたがん診断の技術改善は、市場成長の有利な機会を生み出しています。
主な市場の統計 | |
---|---|
基準年[2023] | 2億2,038万米ドル |
予測年[2024] | 2億6,628万米ドル |
予測年 [2030] | 8億6,250万米ドル |
CAGR(%) | 21.52% |
地域別インサイト
米国とカナダを含む米国地域では、早期発見と個別化医療が重視され、AIベースのがん診断への需要が高まっています。著名な研究機関や企業はAI研究に多額の投資を行っており、FDAなどの調査機関はAI診断ツールの承認を急いでいます。企業や学術機関によるAIの特許出願は、画像診断やゲノムデータ解析のための機械学習アルゴリズムの技術革新を反映しています。プライバシーや精度に関する懸念が払拭されれば、顧客はAIを活用したヘルスケア・サービスを一般的に受け入れています。EU諸国の多くは、政府のイニシアチブを通じて、ヘルスケア分野における包括的なAIの研究開発活動に取り組んでいます。同地域では、人口の高齢化とがん罹患率の増加により、がん診断におけるAIに対する顧客ニーズが高いです。顧客の購買行動については、欧州では厳しいGDPR規制に準拠した製品やサービスが好まれる傾向にあります。中東では、スマートヘルス技術に多額の投資が行われており、AIがん診断ツールの市場が拡大しています。APAC地域では、高齢化が消費者ニーズを牽引し、がん診断におけるAIの市場が拡大しています。APAC地域では、顧客はますます技術に精通し、AIヘルスケアソリューションに前向きになっており、また、政府によるAI研究の支援ががん診断におけるAIの急成長市場を確立しています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、がん診断におけるAI市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、がん診断におけるAI市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査対象期間の累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、がん診断におけるAI市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[193 Pages Report] The AI in Cancer Diagnostics Market size was estimated at USD 220.38 million in 2023 and expected to reach USD 266.28 million in 2024, at a CAGR 21.52% to reach USD 862.50 million by 2030.
Artificial Intelligence (AI) in cancer diagnostics involves the use of advanced algorithms and software to process, analyze, and interpret medical images and data for the detection, diagnosis, and prediction of cancer. These AI-driven systems are equipped with machine learning and deep learning capabilities, which enable them to learn from vast amounts of oncological data, improving their accuracy and efficiency over time. The increasing prevalence of cancer among the global population and the rising need for personalized medicine boost the adoption of AI in the healthcare sector. Moreover, proliferating adoption in several cancer screening programs worldwide, along with the exponential shift towards non-invasive cancer diagnosis, drives AI integration in cancer therapy. However, the high cost of AI-integrated cancer therapies and the shortage of trained oncologists impact the expansion of AI in the cancer diagnostics market. Furthermore, technological improvements in cancer diagnostics supported by government investments create lucrative opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 220.38 million |
Estimated Year [2024] | USD 266.28 million |
Forecast Year [2030] | USD 862.50 million |
CAGR (%) | 21.52% |
Regional Insights
In the American region, including the United States & Canada, the demand for AI-based cancer diagnostics is driven by a strong emphasis on early detection and personalized medicine. Prominent institutions and companies are investing heavily in AI research, and regulatory agencies such as the FDA are expediting approvals of AI diagnostic tools. Patent filings in AI from companies and academic institutions reflect the innovation in machine learning algorithms for imaging and genomic data analysis. Customers are generally receptive to AI-driven healthcare services, provided privacy and accuracy concerns are addressed. A host of EU countries engage in comprehensive AI research and development activities in the healthcare sector through government initiatives. The region shows a strong customer need for AI in cancer diagnostics due to aging populations and increased cancer prevalence. In terms of customer purchasing behavior, Europeans tend to favor products and services that comply with stringent GDPR regulations. In the Middle East, with substantial investments in smart health technologies, there's a growing market for AI cancer diagnostic tools. APAC region has a growing market for AI in cancer diagnostics, with its aging population driving consumer needs. In the APAC region, customers are increasingly tech-savvy and open to AI healthcare solutions, while the government's support of AI research has established a burgeoning market for AI in cancer diagnostics.
Market Insights
The market dynamics represent an ever-changing landscape of the AI in Cancer Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the AI in Cancer Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the AI in Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer
Biotechnology firm Owkin has solidified a partnership with MSD, known as Merck & Co. in the United States, to pioneer AI-enhanced digital pathology diagnostics tailored for the European Union market. This groundbreaking collaboration aims to refine pre-screening methods for Microsatellite Instability-High (MSI-H), a genomic biomarker critical for prognosticating and guiding treatment in immunotherapy, specifically in cancers such as endometrial, gastric, small intestine, and biliary where MSI-H detection is currently not standard practice despite its significance. [Published On: 2023-12-19]
ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions
ConcertAI has established a pivotal multi-year strategic partnership with Memorial Sloan Kettering Cancer Center (MSK) to focus on driving the advancement and implementation of clinical AI algorithms and enhancing imaging workflow integration within clinical trials, as well as augmenting oncology clinical decisions. MSK heralds these advancements as a catalyst for precise diagnostics and better management of treatment, fueling a transformative shift within the radiology and AI community that promises a leap in cancer diagnosis and patient care. [Published On: 2023-11-14]
Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses
F. Hoffmann-La Roche Ltd. has announced collaborations with Ibex Medical Analytics and Amazon Web Services to enhance cancer diagnostics through the navify digital pathology platform, which integrates cutting-edge AI tools for improved accuracy and efficiency in diagnosing breast and prostate cancer. These innovative collaborations aim to streamline pathology workflows by providing secure access to AI-driven decision support, enabling pathologists to deliver precise and expedited patient care. [Published On: 2023-10-26]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the AI in Cancer Diagnostics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.
Market Segmentation & Coverage